Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of
alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates
of about 30% of individuals in the United States. A subset of these will develop progressive
disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis
and liver failure. NAFLD is expected to be the most common indication for liver
transplantation by the year 2020. We hypothesize that growth hormone (GH) replacement will
decrease intrahepatic lipid accumulation as quantified by 1H magnetic resonance spectroscopy
(1H-MRS).